Anifrolumab (Saphnelo) is a fully human IgG1 targeting type I interferon receptor subunit 1 (IFNAR1) approved in 2021 for moderate to severe systemic lupus erythematosus (SLE). The gene discussed is IFNAR1; the disease is systemic lupus erythematosus.